John Theurer Cancer Center | Strategic Alliance Partners

Mutahar Ahmed, MD, FACS, details the transvesical surgical approach for radical prostatectomy.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

Noa Biran, MD, highlighted the real-world use of the SKY92 gene expression profiling assay for multiple myeloma risk stratification.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Dr Phull reviews findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma.

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Liquid biopsy offers a revolutionary approach for detecting relapse in patients with AML post stem cell transplant, potentially enhancing early intervention.

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Rosario Ligresti, MD, FASGE, discusses the rising incidence of appendix cancer, lack of optimal treatment modalities, and unmet needs for these patients.

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Geoffrey B. Pelz, MD, discusses the evolution of thoracic surgical oncology, along with newer minimally invasive approaches to surgery in lung cancer.

The oral formulation of decitabine-cedazuridine helps empower patients with MDS or CMML to maintain their quality of life from the comfort of their home.

Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.

Martin E. Gutierrez, MD, discusses data for Dato-DXd plus rilvegostomig in advanced or metastatic NSCLC.

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Hackensack Meridian JFK University Medical Center has expanded its comprehensive cancer care services with the opening of a newly renovated, four-story facility at 80 James Street in Edison, NJ

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Hackensack Meridian Jersey Shore University Medical Center experts have successfully treated their first patients using RenovoRx’s Novel Trans-Arterial Micro-Perfusion therapy platform.

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

Faculty at Hackensack Meridian School of Medicine developed a novel curriculum to improve medical training through practical, clinic-focused learning.

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.